Korean, Foreign Pharms Call For ‘Reasonable’ Drug Price System
This article was originally published in PharmAsia News
South Korean and foreign pharma firms have jointly urged the Korean government to postpone a planned drug price cut by one year in an effort to overcome the impact of the MERS outbreak, and have promised to cooperate to propose a balanced new drug pricing system as well as to recommend steps to promote better R&D in the sector.
You may also be interested in...
Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Korean venture Helixmith faces another setback following a missed Phase III endpoint for its plasmid DNA neuropathy candidate, with its shares plunging after it warned of a possible delay in a planned rights offering, amid concerns from minority shareholders over other investment losses.